Head and Neck Cancers

Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC

February 25, 2021

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.

FDA Expands Gardasil 9 Approval for HPV-Related Cancers

June 15, 2020

On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.

Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer

May 16, 2019

A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.